Aspirin prophylaxis is recommended for women at higher risk of preeclampsia; yet, there is no consensus about the optimal dose.
individual participant data (IPD). 1 In response, we evaluated the efficacy of aspirin at different doses, using IPD from a large metaanalysis of preeclampsia prevention 1 and then compared those findings to that of the recent Aspirin for Evidence-based Preeclampsia Prevention trial (ASPRE). 4 
STUDY DESIGN:
We included 22 primary RCTs that compared daily aspirin to placebo among 30,532 women at higher risk of preeclampsia. 1 Trials that administered antiplatelet agents other than aspirin were excluded.
FIGURE

Efficacy of daily aspirin doses of £81 or >81 mg
Assessed from pooled analyses of individual participant-level data from randomized clinical trials (black squares) or the Aspirin for Evidence-based Preeclampsia Prevention trial (red circles). The outcomes are preeclampsia (upper portion) and preeclampsia with preterm birth (lower portion).
ASPRE, Aspirin for Evidence-based Preeclampsia Prevention trial; CI, confidence interval; RCT, randomized controlled trial.
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Research Letter ajog.org Evaluated outcomes were (1) preeclampsia (hypertension with new-onset proteinuria 20 weeks gestation), (2) preeclampsia with preterm birth (PTB) at <37 weeks gestation. First, binomial mixed-effect models with a random intercept for trial effects produced relative risks (RR) for aspirin at doses of 81 mg and >81 mg, each relative to placebo control. Second, trial-adjusted predicted event rates for preeclampsia and preeclampsia with PTB were calculated by aspirin dose 1 and contrasted with the respective event rates in the recent ASPRE trial that evaluated aspirin 150 mg daily. 4 
RESULTS:
First, in the 22 previous RCTs that used IPD, preeclampsia was reduced at aspirin doses of 81 mg (pooled RR, 0.92; 95% confidence interval [CI], 0.85e0.99) and more so at doses of >81 mg (pooled RR, 0.74; 95% CI, 0.60e0.92), the latter comparable with that of the ASPRE trial (RR, 0.72; 95% CI, 0.54e0.98; Figure) . Figure) . Adjusting for gestational age at randomization, baseline maternal chronic hypertension, prepregnancy diabetes mellitus, renal disease, age, multiple pregnancy, and multiparty did not alter these findings (data not shown). Second, among the pooled RCTs, preeclampsia and preeclampsia with PTB declined with increasing aspirin doses, but with overlapping confidence intervals (data not shown). In these pooled RCTs that used IPD, the lowest predicted rate of preeclampsia with PTB (1.6%) was observed at a daily dose of 100 mg, the same rate as in the ASPRE trial (1.6%). 4 
CONCLUSION:
This analysis suggests a dose-response effect of aspirin for the prevention of preeclampsia and preeclampsia with PTB up to 150 mg daily, but with ongoing uncertainty. A future RCT might compare higher (eg, 150 or 162 mg) vs lower (eg, 81 mg) doses of aspirin in women who exceed a certain risk threshold for the development of preeclampsia. 5 Establishing the optimal dose of aspirin for the prevention of preeclampsia and related prematurity could benefit millions of pregnant women and their fetuses worldwide at a very low cost and risk.
